Rajib Dhar,Arikketh Devi
Rajib Dhar
Cancer is an unsolved health crisis worldwide. Extracellular vesicles (EVs) address this problem in a new way. In cancer, early detection is highly challenging, exosomes (a subpopulation of EVs, originating from endosomes) overcomes this li...
Liquid biopsy for assessment of RFS (recurrence-free survival) in NSCLC (non-small cell lung cancer) patients post-treatment through circulating tumour DNA detection: A meta-analysis [0.03%]
通过检测循环肿瘤DNA来评估非小细胞肺癌患者治疗后的无复发生存率的液体活检：一项荟萃分析
Urvi Zala,Rushi Patel,Viraj Panchal et al.
Urvi Zala et al.
Background: One of the main techniques for diagnosing lung cancer is still tissue biopsy. The more recent liquid biopsy technique includes the assessment of fragments of cfDNA, ctDNA, and CTCs, which are released by tumou...
Circulating epithelial cell as viral infection and tissue origin marker in patients with severe COVID-19 [0.03%]
重症COVID-19患者中循环上皮细胞作为病毒感染和组织起源的标志物
Valeria Denninghoff,María Del Carmen Garrido-Navas,María Del Pilar Molina-Vallejo et al.
Valeria Denninghoff et al.
Liquid biopsy (LB) is a minimally invasive procedure that detects biomarkers in body fluids for real-time monitoring of patients. This study developed a new LB approach to analyze Circulating Epithelial Cells (CECs) in Intensive Care Unit (...
Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications [0.03%]
乳腺癌患者循环肿瘤细胞中HER2状态的实时评估：检测方法及其临床意义
Eleonora Nicolò,Mara Serena Serafini,Laura Munoz-Arcos et al.
Eleonora Nicolò et al.
The human epidermal growth factor receptor 2 (HER2) plays a central role in breast cancer (BC). Therefore, it is critical to develop a method that can capture its spatial and temporal heterogeneity. Nowadays, therapeutic decisions for BC pa...
Liquid biopsy kinetics and detection of ERBB2 amplification/HER2-positivity in refractory hepatocellular carcinoma [0.03%]
液体活检动力学及耐药肝细胞癌中ERBB2扩增/HER2阳性的检测
Aaditya Srivant Geddam,Areeb Lutfi,Maaz Khan Afghan et al.
Aaditya Srivant Geddam et al.
Hepatocellular Carcinoma (HCC) is the most common primary liver carcinoma, accounting for 75-85% of all cases. For patients with advanced unresectable and/or metastatic HCC, treatment options primarily include immunotherapy combinations and...
"Plasma-first" approach for molecular genotyping in non-small cell lung cancer: A narrative review [0.03%]
非小细胞肺癌分子基因分型的“血浆优先”方法：一项叙述性回顾
Miguel García-Pardo,Natasha Leighl
Miguel García-Pardo
Molecular genotyping is essential for management of patients newly diagnosed with advanced non-small cell lung cancer (NSCLC). Plasma circulating tumor DNA (ctDNA) testing has emerged as a complement to tumor tissue genotyping for advanced ...
Harnessing liquid biopsies: Exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine [0.03%]
液体活检的临床应用：外泌体和ctDNA作为精准癌症医学中的一种微创型生物标志物
Oluwaseun Adebayo Bamodu,Chen-Chih Chung,Thomas R Pisanic nd
Oluwaseun Adebayo Bamodu
Liquid biopsies have emerged as groundbreaking tools for minimally invasive monitoring of cancer, encompassing the analysis of Cell-Free DNA (cfDNA), circulating tumor DNA (ctDNA) and exosomes. This paradigm shift offers an emerging approac...
Divya Mirgh,Anand Krishnan,Sukhamoy Gorai
Divya Mirgh
Advancements in precision oncology: Investigating the function of circulating DNA in the advancement of liquid biopsy technologies [0.03%]
精准肿瘤学的进步：探究循环DNA在液体活检技术进步中的功能
Stootee Baruah,Jenifer Rajak,Arup Kumar Mitra et al.
Stootee Baruah et al.
While the traditional method is a biopsy of the potential tumor tissue, more non-invasive methods have been developed such as the liquid biopsy. It is an emerging, powerful cancer detection method that is used for molecular profiling of tum...
Unveiling the impact of corticosteroid therapy on liquid biopsy-detected cell-free DNA levels in meningioma and glioblastoma patients [0.03%]
皮质类固醇治疗对脑膜瘤和胶质母细胞瘤患者液态活检中游离DNA水平影响的揭示
Veronica Aran,Jose Orlando de Melo Junior,Carlos Pilotto Heming et al.
Veronica Aran et al.
The liquid biopsy era has brought several possibilities to improve precision in patient care. Among the different sources of analytes, the cfDNA has been explored as a possible disease indicator, especially in cancer. Intracranial tumors st...